HealthDay News — Administration of inhaled nitrite is not associated with improvement in exercise capacity compared with placebo among patients with heart failure with preserved ejection fraction (HFpEF), according to a study published in the November 6 issue of the Journal of the American Medical Association.

Barry A. Borlaug, MD, from the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a multicenter, two-treatment crossover trial involving 105 patients with HFpEF. Participants were randomly assigned to 4 weeks of inorganic nitrite or placebo administered via a micronebulizer device followed by a 2-week washout period with no study drug for each 6-week phase of the crossover study. 

Related Articles

The researchers observed no significant difference in mean peak oxygen consumption in the nitrite phase vs the placebo phase (13.5 vs 13.7mL/kg/min; P=.27). No significant between-treatment phase differences were observed in daily activity levels (5497 vs 5503 accelerometry units; P=.91), Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (62.6 vs 61.9; P=.39), functional class (2.5 vs 2.5; P=.43), echocardiographic E/e’ ratio (16.4 vs 16.6; P=.93), or N-terminal fragment of the prohormone brain natriuretic peptide levels (520 vs 533pg/mL; P=.74). Worsening heart failure occurred in 2.9 and 7.6% of participants during the nitrite phase and placebo phase, respectively.

“These results are in contrast to multiple earlier studies suggesting administration of inorganic nitrite or nitrate may have benefits in HFpEF,” the authors write.

Continue Reading

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Abstract/Full Text
Editorial (subscription or payment may be required)